U.S. FDA Panel Votes Against Reliability Of Late-Stage Data For Amgen's Lung Cancer Drug
Portfolio Pulse from Benzinga Newsdesk
A U.S. FDA panel has voted against the reliability of late-stage data for Amgen's lung cancer drug. This could potentially impact the approval process of the drug.
October 05, 2023 | 6:39 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The FDA panel's vote against the reliability of late-stage data for Amgen's lung cancer drug could potentially delay or hinder the approval process, negatively impacting Amgen's stock in the short term.
The FDA's approval process is critical for pharmaceutical companies like Amgen. Any negative news or doubts about the reliability of drug data can potentially delay or hinder the approval process, which can negatively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100